Analytical Data
-
Gene name
CG-3
- Application
-
Alternative Names
(CG-alpha-1)(Beta-conglycinin alpha subunit)(allergen Gly m 5)
-
Species
Glycine max
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0DO16
-
Expression Region
194-605aa
-
Molecular Weight
54.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CG-3, a recombinant protein derived from the junctional region of the human complement component C3, has garnered significant attention in recent years due to its potential therapeutic applications and roles in immune system modulation. Research indicates that CG-3 plays a crucial role in the regulation of the complement system, an integral part of the innate immune response, which is involved in pathogen clearance and inflammatory processes. Understanding the structure and function of CG-3 may pave the way for novel treatments for autoimmune diseases, where dysregulation of the complement system is implicated, as well as for enhancing vaccine efficacy by improving antigen presentation. Additionally, CG-3's ability to interact with various immune cells suggests it could serve as a biomarker for disease states or a target for drug development. As studies advance, elucidating the mechanisms through which CG-3 influences immune responses will provide deeper insights into its therapeutic potential, making it a focus of ongoing investigations in immunology and biotechnology fields.
